Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)

International Clinical Psychopharmacology

Volumn 9, Issue , 1994, Pages 19-26

  Hyttel, J ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Citailopram; Fluoxetine; Fluvoxamine; Paroxetine; Receptor binding; Sertraline; SSRI; Uptake inhibition

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; MIANSERIN; NOMIFENSINE; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; BEHAVIOR; BIOCHEMISTRY; HUMAN; NEUROTRANSMISSION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW;

ANIMAL; BRAIN; DEPRESSIVE DISORDER; HUMAN; RECEPTORS, SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTIC TRANSMISSION;

EID: 0028294525     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/00004850-199403001-00004     Document Type: Article

References (36)

1. Andersen PH (1987) Biochemical and pharmacological characterization of pH]GBR 12935 binding in vitro to rat striatal membranes: Labeling of the dopamine uptake complex. Journal of Neurochemistry, 48, 1887-1896.
2. Amt J (1989) Characterization of the discriminative stimulus properties induced by 5-HT, and 5-HT, agonists in rats. Pharmacology and Toxicology, 64, 165-172.
3. Blier P, de Montigny C and Chaput Y (1990) A role for the serotonin system in the mechanism of action of antidepressants. Journal of Clinical Psychiatry, 51, suppl 4, 14-20.
4. Carlsson A and Lindqvist M (1978) Effects of antidepressant agents on the synthesis of brain monoamines. Journal of Neural Transmission, 43, 73-91.
5. Christensen AV, Fjalland B, Pedersen V, Danneskiold-Samspe P and Svendsen O (1977) Pharmacology of a new phthalane (Lu 10-171) with specific 5-HT uptake inhibiting properties. European Journal of Pharmacology, 41, 153-162.
6. Ciarcha G, Smokcum RWJ, Stephenson JD and Weiramanthri TB (1985) Effects of some atypical antidepressants on beta- adrenoceptor binding and adenylate cyclase activity in the rat forebrain. European Journal of Pharmacology, 108, 1-7.
7. Cross JA and Horton RW (1987) Are increases in GABAb receptors consistent findings following chronic antidepressant administration? European Journal of Pharmacology, 141, 159-162.
8. D’Amato R, Largent BL, Snowman AM and Snyder SH (1987) Selective labelling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labelling of multiple sites by PHJimipramine. Journal of Pharmacology and Experimental Therapeutics, 242, 364-371.
9. Fasmer OB, Hunskaar S and Hole K (1989) Antinociceptive effect of serotonergic reuptake inhibitors in mice. Neuropharmacology, 28, 1363-1366.
10. Hoffman BJ, Mezey E and Brownstein MJ (1991) Cloning of a serotonin transporter affected by antidepressants. Science, 254, 579-580.
11. Hyttel I (1982) Citalopram: Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 6, 277-295.
12. Hyttel J and Larsen J-J (1985) Serotonin-selective antidepressants. Acta Pharmacologica et Toxicologica, 56, Suppl 1, 146-153.
13. Hyttel J, Arnt J, Bpgesp K, Christensen AV, Larsen J-J, LembpI HL, Meier E and Sánchez C (1988) Neurochemical and behavioural profile of Lu 17-133, (±)-trans-4-[3-(3,4- dichloropheny1)-indan-1 -y 1]-1 -piperazineethanol, an inhibitor of the uptake of dopamine and noradrenaline. Drug Development Research, 13, 213-230.
14. Johnson AM (1991) The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals. In: Selective Serotonin Re-uptake Inhibitors. Perspectives in Psychiatry, Vol. 1 (Eds JP Feighner and WF Boyer), pp. 37-70. John Wiley, Chichester.
15. Klimek V and Nielsen M (1987) Chronic treatment with antidepressants decreases the number of [3H] SCH 23390 binding sites in the rat striatum and limbic system. European Journal of Pharmacology, 139, 163-169.
16. Kovala T, Leppavuori A and Putkonen P (1987) Sleep in cats after a new 5-HT uptake inhibiting drug: Lu 10-171. Acta Physiologica Scandinavica, 102, 74A-75A.
17. Langer SZ, Raisman R and Briley M (1981) High-affinity [3H]DMI binding associated with neuronal noradrenaline uptake in the periphery and the central nervous system. European Journal of Pharmacology, 12, 423-424.
18. Maitre L, Moser P, Baumann PA and Waldmeier PC (1980) Amine uptake inhibitors: Criteria of selectivity. Acta Psychiatrica Scandinavica, 61, Suppl 280, 97-110.
19. Maj J, Rogdz Z, Skuza G and Sowinska H (1989) Antidepressants given repeatedly increase the behavioural effect of dopamine D-2 agonist. Journal of Neural Transmission, 78, 1-8.
20. Melia KF and Spealman RD (1991) Pharmacological characterization of the discriminative-stimulus effects of GBR 12909. Journal of Pharmacology and Experimental Therapeutics, 258, 626-632.
21. Mellerup ET, Plenge P and Engelstoft M (1983) High affinity binding of [3H]paroxetine and [3H]imipramine to human platelet membranes. European Journal of Pharmacology, 96, 303-309.
22. Ortmann R, Waldmeier PC, Radeke E, Felner A and Delini-Stula A (1980) The effects of 5-HT uptake- and MAO-inhibitors on L-5-HTP-induced excitation in rats. Archives of Pharmacology, 311, 185-192.
23. Pile A and Lloyd KG (1984) Chronic antidepressants and GABA “B” receptors: A GABA hypothesis of antidepressant drug action. Life Sciences, 35, 2149-2154.
24. Plenge P and Mellerup ET (1991) [3H]Citalopram binding to brain platelet membranes of human and rat. Journal of Neurochemistry, 56, 248-252.
25. Plenge P, Mellerup ET and Laursen H (1991) Affinity modulation of [3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and platelets. European Journal of Pharmacology, 206, 243-250.
26. Porsolt RD (1981) Behavioral despair. In: Antidepressants: Neurochemical, Behavioral and Clinical Perspective (Eds SJ Enna, JB Malick and E Richelson), pp. 121-139. Raven Press, New York.
27. Porsolt RD, Bertin A, Blavet N, Deniel M and Jalfre M (1979) Immobility induced by forced swimming in rats; Effects of agents which modify central catecholamine and serotonin activity. European Journal of Pharmacology, 57, 201-210.
28. Raisman R and Langer SZ (1983) Specific high affinity [3H]imi-pramine binding sites in rat lung are associated with a nonneuronal uptake site for serotonin. European Journal of Pharmacology, 94, 345-348.
29. Raisman R, Sette M, Pimoule C, Briley M, Langer SZ (1982) High-affinity [3H]desipramine binding in the peripheral and central nervous system: A specific site associated with the neuronal uptake of noradrenaline. European Journal of Pharmacology, 78, 345-351.
30. Richelson E and Nelson A (1984) Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro, Journal of Pharmacology and Experimental Therapeutics, 230, 94-102.
31. Scherschlicht R, Pole P, Schneeberger J, Steiner M and Haefely W (1982) Selective suppression of rapid eye movement sleep (REMS) in cats by typical and atypical antidepressants. In: Typical and Atypical Antidepressants. Molecular Mechanisms. Advances in Biochemical Psychopharmacology, Vol. 31 (Eds E Costa and G Racagni), pp. 359-364. Raven Press, New York.
32. Sugrue MF (1979) On the role of 5-hydroxytryptamine in drug- induced antinociception. British Journal of Pharmacology, 65, 677-681.
33. Sulser F and Mishra R (1982) Regulation of central noradrenergic receptor function and its relevance to the therapy of depression. In: New Vistas in Depression (Eds SZ Langer, R Takahashi and M Briley), pp. 37-47. Pergamon Press, Oxford.
34. Thomas DR, Nelson DR and Johnson AM (1987) Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxy-tryptamine uptake inhibitor. Psychopharmacology, 93, 193-200.
35. Vaastra WJ, Deiman-Van Aalst WMA and Eigeman L (1981) DU 24565, a quipazine derivative, a potent selective serotonin uptake inhibitor. European Journal of Pharmacology, 70, 195-202.
36. Vetulani J, Antkiewicz-Michaluk L, Rokosz-Pelc A and Pile A (1984) Alpha up-beta down adrenergic regulation; A possible mechanism of action of antidepressant treatments. Polish Journal of Pharmacology and Pharmacy, 36, 231-248.